Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients

Posted Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC. (WRAL Tech Wire)

Related: Campus Connections

UNC Army ROTC earns prestigious MacArthur Award
UNC-Chapel Hill’s Army ROTC program has been named a recipient of the prestigious Gen. Douglas MacArthur Award for the fifth time in its history, recognizing...
Thu Jun 11, 2026

UNC alum, Forbes 30 Under 30 honoree Anne Marie Hagerty is ‘The Envoy’
Anne Marie Hagerty travels the world interviewing people for “The Envoy Show,” a docuseries about how food impacts health, economic growth and sustainable tourism in...
Wed Jun 10, 2026

UNC-Founded Eats2Seats to Create Entrepreneurial ‘Third Space’ with New Franklin Street Headquarters
Like an Uber Eats for sports and entertainment venues, the concessions and vending partner Eats2Seats allows fans to order food and beverages right to their...
Tue Jun 9, 2026

'You can't escape the story': UNC class feels for indentations on Old East left by enslaved laborers
A class of first-year students spent an hour carefully running their hands along the grooves of Old East's brick exterior. Their goal? To find...
Sun Jun 7, 2026